Company profile
Dyadic International, Inc.
NASDAQ: DYAI · Healthcare · Biotechnology
#751 of 1,422 Healthcare companies by revenue31st-percentile growth
EA Score
39DFH 29DQ 46GM 49SS 47
v0.1 · 65/100 weight · provisional
↑ growth stability, listing tenure · ↓ return on equity, workforce scale
Methodology →Revenue TTM
$3.0M
Rev growth YoY (TTM)
-11.0%
Net income (FY)
-$7.4M
Employees
5
as of 2026-08-20
Market cap
$26.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.1M$3.1M2025
Net income-$7.4M-$7.4M2025
Operating income-$7.2M-$7.2M2025
Total assets$9.9M$9.9M2025
Liabilities$8.7M$8.7M2025
Equity$1.2M$1.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Grant60%
Research and Development31%
License9%
By geography
Not disclosed.
The read
What is Dyadic International, Inc.’s revenue?
Dyadic International, Inc. booked $3.1M in FY2025 revenue, contracting 12% year over year — slower than 69% of Healthcare companies we track, at a -238.3% net margin.
Peers · Healthcare
Aptevo Therapeutics Inc.35DAvitar, Inc.——Aridis Pharmaceuticals, Inc.——Polarean Imaging plc——Numinus Wellness Inc.——Intelligent Bio Solutions Inc.40DNeighbors
Palm Beach →Key facts
CEOMark A. Emalfarb
SectorHealthcare
IndustryBiotechnology
HeadquartersJupiter, FL
ExchangeNASDAQ: DYAI
Employees5
IPO date2008-01-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.